ClinicalTrials.gg
CompletedNCT06843460Updated Feb 25, 2025

A Clinical Study of MK-7962 in Healthy Chinese Participants (MK-7962-021)

A Phase 1 interventional study of Sotatercept and Placebo in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-25.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2024, 2 years 5 months ago, and no results have been posted to the registry.
  • Registered 1 year 2 months after the study started (first participant enrolled Nov 2023, registered Feb 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The goal of this study is to learn about the safety of 2 different amounts of sotatercept and if healthy Chinese people tolerate them. The study will also measure what happens to sotatercept in a person's body over time (pharmacokinetic or PK study).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Is in good health
  • Has a ≥18.0 kg/m\^2 and ≤28.0 kg/m\^2

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has a history of endocrine, GI, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Has been treated with a sotatercept or luspatercept
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Sotatercept Dose Level 1

    Participants received a single dose of sotatercept at dose level 1.

    Biological: Sotatercept

  • Experimental
    Sotatercept Dose Level 2

    Participants received a single dose of sotatercept at dose level 2.

    Biological: Sotatercept

  • Placebo comparator
    Placebo

    Participants received a single dose of placebo to sotatercept.

    Other: Placebo

Interventions

  • BiologicalSotatercept

    Single subcutaneous injection

    Also known as: MK-7962, ActRIIA-IgG1Fc, ACE-011

  • OtherPlacebo

    Single subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 120 days

  2. Number of Participants Who Discontinue Study Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study due to an AE will be reported.

    Time frame: Up to approximately 120 days

  3. Maximum Serum Concentration (Cmax) of Sotatercept

    Blood samples will be collected to determine the Cmax of sotatercept.

    Time frame: At designated timepoints (up to 120 days)

  4. Time to Maximum Serum Concentration (Tmax) of Sotatercept

    Blood samples will be collected to determine the Tmax of sotatercept.

    Time frame: Predose and at designated timepoints up to 120 days postdose

  5. Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of MK-7962

    Blood samples will be collected to determine the AUC0-last of MK-7962.

    Time frame: At designated timepoints (up to 120 days)

  6. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of MK-7962

    Blood samples will be collected to determine the AUC0-inf of MK-7962.

    Time frame: At designated timepoints (up to 120 days)

  7. Area Under the Concentration-Time Curve from Time 0 to 28 days (AUC0-28 days) of MK-7962

    Blood samples will be collected to determine the AUC0-28 days of MK-7962.

    Time frame: At designated timepoints (up to 28 days postdose)

  8. Apparent Terminal Half-life (t1/2) of MK-7962

    Blood samples will be collected to determine the t1/2 of MK-7962.

    Time frame: At designated timepoints (up to 120 days)

  9. Apparent Clearance (CL/F) of MK-7962

    Blood samples will be collected to determine the CL/F of MK-7962.

    Time frame: At designated timepoints (up to 120 days)

  10. Apparent Volume of Distribution During Terminal Phase (Vz/F) of MK-7962

    Blood samples will be collected to determine the Vz/F of MK-7962.

    Time frame: At designated timepoints (up to 120 days)

07

Study locations

1 site
  • Zhongshan Hospital,Fudan University-Dep. of Clinical Pharmacology (Site 0001)
    Shanghai, Shanghai 200032, China
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in May 2024, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2025
First posted
Feb 25, 2025
StartActual
Nov 22, 2023
Primary completionActual
May 21, 2024
CompletionActual
May 21, 2024
Last update
Feb 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06843460
Responsible party
Sponsor
First posted
Feb 25, 2025
Start date
Nov 22, 2023
Primary completion
May 21, 2024
Completion
May 21, 2024
Last update
Feb 25, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotatercept

Start the discussion